From Benchmarks to the Bench: Preference, Correspondence and Selectivity in Bidirectional Drug-Target Screening
Authors
Abstract
Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates. We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved drugs and 614 human proteins. For the same target or drug, pairs of models produced completely disjoint Top-10 molecule and protein lists in 77.8% and 70.1% of comparisons, respectively. Even where recommendations overlapped, agreement between some systems largely reflected recurring preferences for the same candidates. Published inhibition measurements for 79 molecules and 65 kinases revealed that some systems enriched active candidates, yet their hit yields changed little when recommendations were matched to different drugs or targets, whereas other systems lost substantially more hits. Some of the former systems also rarely ranked both molecules and kinases correctly when two drugs favoured different kinases. We further retrained the same architecture on the same data, with the training objective fixed and random seeds varied. Despite similar test performance, mean pairwise Top-10 overlap on a separate screening catalogue was about two candidates. Our study moves DTI model evaluation beyond benchmark performance to assess whether model predictions can guide meaningful experimental decisions in drug discovery and target identification.
Paper Information
- arXiv ID:
- 2611.26369v1
- Published: